Introduction
Glioma is a fatal malignancy in central nervous system (CNS) with a median survival period of only 14 months and a 5-year survival rate ,10% after diagnosis.
1,2 Current means for clinical glioma treatment include surgical resection, radiation, and chemotherapy. In particular, chemotherapy using temozolomide (TMZ) as the standard chemotherapeutic plan has shown ascertained effect to increase the survival rate of patients suffering from this disease. [2] [3] [4] However, owing to the inherent and acquired resistance of glioma cells to TMZ as well as the blood-brain barrier (BBB) impeding the orally or intravenously administered drug to enter the brain, the effect of TMZ chemotherapy is greatly limited. 5 Although the restriction of BBB for drug delivery may be overcome by local drug administration, drug resistance is still a big challenge for TMZ treatment to exert an ideal effect.
Synthetic siRNA has been applied in the therapeutic studies of various diseases including cancer. 6 As a major agent for gene therapy, siRNA exhibits not only high efficiency to induce target gene silencing but also enhanced safety compared to DNA as it only interferes with the posttranscriptional process. 7, 8 Previous studies have shown that upregulated expressions of antiapoptotic proteins may make cancer cells less sensitive to chemotherapy, which is known as a non-pump resistance. 9, 10 As a major antiapoptosis protein, BCL-2 impedes the mitochondrial release of apoptosis activating factor and cytochrome c initiating the caspase cascade. 11 As BCL-2 is overexpressed in a variety of cancer types including glioma, 12 BCL-2 silencing using siRNA is regarded as a promising approach to overcome chemoresistance and promote tumor apoptosis. 13 In this context, a combinative glioma therapy using TMZ and BCL-2 siRNA may result in improved outcome. Nevertheless, the strategy relies on the development of an efficient codelivery system for the two different kinds of therapeutic agents. 14 It is well known that free siRNA is prone to nuclease degradation in vivo and its cell uptake is usually hindered by negative charge. 15 So far, a number of delivery systems including viral and nonviral vectors have been developed to facilitate siRNA therapy. Among the nonviral ones, cationic polymers have been widely studied because of their easy synthesis and good biocompatibility. 16 In particular, poly(ethylenimine) (PEI) is acknowledged as the most promising one not only because it readily complexes siRNA but also because it facilitates the lyosomal escape of nanocarriers through proton sponge effect. 17 However, the issue may become much more complicated in designing vectors for the codelivery purpose. A main reason is that two different types of therapeutic agents often possess very different physicochemical properties and thus require different structural materials to accommodate them.
Up to now, multifunctional nanoplatforms developed for the codelivery purpose mainly include polymeric, liposomal, and silica-based cationic nanoparticles. 18 Surface PEGylation of nanoparticles was generally needed in order to improve the serum stability of nanoparticles and to shield the cationic layer for decreased cytotoxicity. Recently, we have achieved the codelivery of siRNA and chemotherapeutic agents in vitro using the folate-conjugated triblock copolymer of poly(ε-caprolactone) (PCL), PEI, and poly(ethylene glycol) (PEG) (Fa-PEG-PEI-PCL). 19 Cell studies showed that the codelivered siRNA could effectively downregulate the expression of antiapoptosis genes to sensitize ovarian cancer cells to chemotherapeutic drug doxorubicin, 19 which enlightened us to explore whether this concept may work as well in a TMZ-based chemotherapy of glioma, especially in the animal tumor model.
A polymeric micelle (TMZ-FaPEC@siRNA) incorporating TMZ and siRNA targeting the antiapoptosis BCL-2 gene was prepared, as shown in Figure 1 . Through hydrophobic interaction, Fa-PEG-PEI-PCL self-assembled into micelle encapsulating TMZ in the hydrophobic core. Then, siRNA was complexed with the cationic micelle through electrostatic interaction. With folate as targeting molecule on the surface layer, the micelle was expected to be readily internalized into glioma cells, where folate receptor (FR) is significantly overexpressed as compared to normal cells. 20 To explore the therapeutic potential of TMZ-FaPEC@siRNA, the codelivery efficiency, joint effect of BCL-2 silencing and TMZ to induce glioma apoptosis, and tumor growth inhibition were evaluated in glioma C6 cells and animal model. A direct injection of the drug-loaded micelle to the right striatum of animal was adopted in an animal study in consideration that BBB not only prevents drugs from entering the brain but also helps the sequestration of intracranially applied drug.
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Materials and methods Materials
α-Allyl-ε-hydroxy-poly(ethylene glycol) (Allyl-PEG-OH, Mn=2.0 kDa), methoxy-poly(ethylene glycol) (Mn=2.0 kDa), N-hydroxysuccinimide, 1-dodecanol, N,N′-carbonyldiimidazole (CDI), folic acid (Fa), stannous (II) octoate, cysteamine hydrochloride, dicyclohexylcarbodiimide, and triethylamine were purchased from Sigma-Aldrich and used as obtained. TMZ was obtained from Zhejiang Pharmaceutical Co. Ltd (Zhejiang, China). ε-Caprolactone (Sigma-Aldrich) was dried with CaH 2 and purified by vacuum distillation. The scramble siRNA (SCR) and two anti-BCL-2 siRNA duplexes with sequences GGAUGACUGAGUA CCUGAATT (dTdT) as passenger strand, UUCAGGU ACUCAGUCAUCCTT (dTdT) as guide strand were from Genpharm (Shanghai, China). Coumarin 6 and CCK8 cell proliferation assay kit were purchased from Sigma-Aldrich. Cy3-labeled siRNA was provided by Invitrogen Corporation (Carlsbad, CA, USA). The rat C6 glioma cell line overexpressing folate receptors was purchased from American Type Culture Collection. The fluorescent staining agent 4′,6-diamidino-2-phenylindole was obtained from Roche, Germany. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) kit and enhanced chemiluminescence substrate were from Keygen biotech. Co. Ltd (Nanjing, China). Penicillin/streptomycin solution, Roswell Park Memorial Institute-1640 medium (RPMI-1640), and fetal bovine serum (FBS) were purchased from Gibco Life
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Temozolomide for glioma treatment Technology (Carlsbad, CA, USA). Nonfat milk and bovine serum albumin (BSA) were provided by Shanghai Sangon Biotech (Shanghai, China). Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) Apoptosis Detection Kit was supplied by Absin Biochemical Company. Reverse transcriptional polymerase chain reaction (PCR) kit was from Takara (Nojihigashi, Japan) and the qPCR kit was obtained from Roche Diagnostics. All other reagents having analytical or higher purity were used as received.
Preparation of Fa-Peg-PeI-Pcl
Monohydroxyl-terminated polycaprolactone (Mn=2.3 kDa, estimated by proton nuclear magnetic resonance [ 1 H NMR]) was synthesized and activated with CDI to obtain PCL-CDI. Fa-conjugated decorated poly(ethylene glycol)-b-branched poly(ethylene amine) (Fa-PEG-PEI) and methoxy-poly(ethylene glycol)-b-branched poly(ethylene amine) (mPEG-PEI) were synthesized as reported and then further reacted with PCL-CDI to form Fa-PEG-PEI-PCL, abbreviated as FaPEC. 19 
Preparation of TMZ-and sirNa-coloaded micelle
Preparation of TMZ-loaded FaPEC (TMZ-FaPEC) and blank FaPEC cationic micelles (FaPEC) is shown as outlined in Figure 1 . Coumarin-6 (3-(2-benzothiazolyl)-N,Ndiethylumbelliferylamine), which emits green fluorescence under appropriate light stimulation, was used to substitute TMZ for tracking intracellular distribution of the micelle (Coum6-FaPEC). The micelle without folate modification was prepared through the same procedure except that mPEG-PEI-PCL rather than Fa-PEG-PEI-PCL was used.
A predetermined amount of siRNA (eg, 0.02 mg) was mixed with a certain amount of TMZ-FaPEC micelle by gently pipetting for 1 min. The solution was then incubated for 30 min at room temperature. By this means, various siRNA-loaded nanocomplexes (TMZ-FaPEC@siRNA and TMZ-PEC@siRNA) were prepared at different ratios of nitrogen in branched PEI to phosphorus in siRNA, which are generally referred to as N/P ratios. The nanocomplexes without TMZ were prepared by the same procedure. Particle size, zeta potential, and drug-loading content were measured according to our previous report. 19 TMZ release profile was determined as follows: 4 mL sample solution of TMZFaPEC@SCR or TMZ-FaPEC@siRNA in PBS of pH 5.0 or pH 7.4 was transferred into a dialysis bag (molecular weight cutoff, 7 kDa). The dialysis bag was immersed in 8 mL PBS of the same pH in a beaker. The solution was then shaken at 37°C. Four milliliters of solution outside the dialysis bag 
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agarose gel retardation assay
The complexation of siRNA with TMZ-loaded micelle was analyzed by agarose gel electrophoresis. In detail, complexes of SCR (1 μg) were prepared with N/P ratios ranging from 0 to 12 and diluted to 2 μL with 50% glycerol. Then, the samples were transferred to 1% agarose gels containing ethidium bromide (0.5 μg/mL) and ran with Tris-acetate buffer at 120 V for 15 min. DNR Bio-Imaging System (NR Bio-Imaging System Ltd, Israel) was utilized to detect the retardation of siRNA motion.
cell culture and transfection
Rat glioma C6 cells were cultured as previously reported. 16 Cells were seeded in 24-well plates with ~1×10 4 cells in each well. Subsequently they were incubated for 12 h in 1 mL of RPMI-1640 with 10% FBS, 4 h in 1 mL of Fa-deficient and FBS-free RPMI-1640, and another 2 h after adding micelle to the medium at an siRNA concentration of 25 nM. For the free folate inhibition assay, cells were pretreated with folate (1 mg/L) for 30 min before the targeting micelle was added to the culture medium. Intracellular distribution of the nanoparticles was observed with confocal laser scanning microscopy. Cell transfection efficiency was measured by flow cytometry.
cell viability assay CCK8 assay was conducted to assess the cytotoxicity of the nanocomplexes. C6 cells were seeded in 96-well plates at 1×10 3 cells per well and then incubated for 12 h in 100 μL of RPMI-1640 containing 10% FBS. They were then incubated for 96 h in the Fa-deficient and FBS-free medium containing the following samples: 1) PEG-PEI-PCL micelle carrying SCR (PEC@SCR); 2) Fa-PEG-PEI-PCL micelle carrying SCR (FaPEC@SCR); 3) Fa-targeted micelle loading TMZ and siRNA (TMZ-FaPEC@siRNA, TMZ-FaPEC@SCR); and 4) non-Fa-targeting micelle loading TMZ and siRNA (TMZ-PEC@siRNA, TMZ-PEC@SCR). siRNA concentration was 20 nM in each well for all groups. The medium was then changed to 150 μL serum-free growth medium and 100 μL 1640 medium containing 10 μL CCK8. After an additional 4 h incubation, the absorbance of formazan crystals was measured on Infinite F200 Multimode plate reader (Tecan, Crailsheim, Germany) at 450 nm after 4 h incubation. All experiments were conducted in triplicate.
cell apoptosis
The C6 cells were cultured overnight at 37°C at 1×10 5 cells per well in six-well plates. After 48 h incubation with different micelle formulations (TMZ-FaPEC@siRNA, TMZPEC@siRNA, TMZ-FaPEC@SCR, FaPEC@siRNA, and free TMZ), the cells were trypsinized, collected, and washed with PBS, and resuspended in 500 μL binding buffer added with 5 μL Annexin V-FITC as well as PI solution. After the cells were incubated for another 15 min, cell apoptosis was evaluated by flow cytometry. The excitation and emission wavelengths for Annexin V-FITC were 488 and 530 nm, and for probes PI were 536 and 617 nm, respectively.
Molecular biology assays in vitro
Expressions of BCL-2 and Bax at mRNA and protein levels were evaluated by real-time PCR (RT-PCR) and Western blot assays as previously reported. 19 Briefly, C6 cells were treated with RIPM lysis and extraction buffer (Beyotime, Shanghai, China) according to the manufacturer's protocol. The extracted total protein was quantified using BCA assay (ThermoFisher, Waltham, MA, USA). Thirty micrograms of protein separated through 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis was electrotransferred onto the polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). The membranes were washed with TBST, blocked by 5% of skim milk, and incubated at 4°C for 12 h with rabbit antibodies against BCL-2 and Bax (1:1,000 dilution, Abcam, USA) as well as rabbit antibody against β-actin (1:1,000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) as an internal standard for normalizing protein expressions. After 1 h incubation with goat anti-rabbit immunoglobulin G (IgG) horseradish peroxidase (1:3,000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) to amplify the signal, the membranes were subjected to chemiluminescent detection.
rat c6 glioma model
In vivo studies were carried out with male Sprague Dawley rats (250-280 g). Animal experiments were approved by the Institutional Animal Care and Use Committee of the Sun YatSen University. Animals received care following the National Laboratory Animal Management Regulations (China, 1988) and Guidance on the Treatment of Experimental Animals (China, 2006) . The in situ glioma model was constructed by the stereotactic implantation of C6 cells according to literature. 22 Briefly, C6 cells dispersed in 20 μL serum-free 
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In vivo studies
Five days after the implantation, the 40 rats were evenly divided into five groups and injected with PBS, TMZFaPEC@siRNA, TMZ-PEC@siRNA, TMZ-FaPEC@SCR, and FaPEC@siRNA, respectively. Treatments were given every four days at the doses of 120 μg/kg TMZ and 1.6 μg/kg siRNA. The five injection points for each treatment were 4, 4.5, 5, 5.5, and 6 mm away from the dura, respectively, and the needle was kept still for 5 min before retraction. Twentyfive days after the first injection, Gd-DTPA (Bayer Schering Pharma AG, Berlin, Germany) was intravenously administered at a dose of 150 μL/kg, and then the rats were subjected to magnetic resonance imaging (MRI) for the measurement of tumor volume. T1-weighted sequence was employed to acquire images as reported. 19 The mean tumor volume (mm 3 ) was calculated as π×a×b×c/2, in which a, b, and c represented coronal long diameter, coronal short diameter, and sagittal long diameter, respectively.
histology and immunohistochemistry
Tumors from the killed rats were fixed by 10% formalin in PBS for 24 h. Hematoxylin and eosin (H&E) staining was conducted to observe the histologic changes of the tissue, with at least five sections examined for each rat. Cell apoptosis was evaluated by TUNEL assay with an In Situ Cell Death Detection Kit (Roche, USA) following the manufacturer's protocol. The expression of BCL-2 was evaluated by immunohistochemistry study. Briefly, after deparaffinization, the sections were were treated with 10 mM citrate buffer for 15 min at 90°C and 0.3% hydrogen peroxide in methanol for 30 min at 4°C. After being blocked by 2% BSA, 10% normal horse serum, and 0.5% Triton X-100, the slides were incubated with rabbit anti-BCL-2 and anti-Bax antibodies (1:500 diluted in PBS/ Tween; Cell Signaling Technology, Danvers, USA) for 1 h and with horseradish-conjugated donkey anti-rabbit IgG secondary antibodies (DAKO Corporation, Carpinteria, CA, USA) for another 1 h at 37°C. The sections were eventually incubated in diaminobenzidine solution for peroxidase visualization.
statistical analysis
One-way analysis of variance and two-tailed Student's t-test were employed to analyze the data, with P-value ,0.05 considered statistically significant.
Results
Preparation and characterization of TMZ-FaPec@sirNa
The folate-modified triblock copolymer PEG-PEI-PCL was synthesized through multistep reactions as outlined in Figure 1 , and characterized by 1 H NMR spectrum (Figure 2) . Apart from the signals attributed to PEG-PEI-PCL, the characteristic peaks for folate were clearly observed as well. The Fa-targeted and TMZ-loaded micelle (TMZ-FaPEC) was prepared by self-assembly of copolymer. The hydrophobic TMZ was encapsulated into the micelle core through hydrophobic interaction with the PCL matrix. According to dynamic light scattering (DLS) detection, TMZ-FaPEC possessed a diameter of 68±7 nm and a zeta potential of +34.1±2.7 mV. A spherical morphology and relatively uniform size distribution were observed by transmission electron microscope (TEM; Figure 3A and B).
Owing to its high positive surface charge, TMZ-FaPEC easily complexed with BCL-2-siRNA to form the TMZ-and siRNA-coloaded micelle (TMZ-FaPEC@siRNA). Agarose gel electrophoresis revealed the siRNA complexation ability of Fa-PEC and nontargeted PEC at different N/P ratios. It is well known that naked siRNA is negatively charged, which accounts for their motion in an electric field. Nevertheless, once siRNA has been complexed with positively charged polymers, such motion in an electric field will no longer be observed because of the loss of siRNA negative charge. Therefore, gel electrophoresis was performed to evaluate the siRNA complexation of cationic micelles. For both FaPEC and PEC, a complete retardation of siRNA motion was observed with N/P ratio above 4 ( Figure 3C ), indicating a thorough complexation of siRNA regardless of folate targeting.
The effect of siRNA complexation on the physical properties of TMZ-FaPEC@siRNA is shown in Figure 3A . According to DLS measurements, when N/P ratio increased, the zeta potential of micelle increased, whereas the particle size decreased, which indicated the successful siRNA complexation ( Figure 3A) . In other words, complexation of siRNA with the PEI chain of micelles led to more compact interlayer and thus decreased the micelle size, and meanwhile the complexed siRNA partially neutralized the positive charge of TMZ-FaPEC. At N/P 10, the micelle showed a relatively small size of 54±4 nm and a weak positive charge of 12.4±1.4 mV, which would facilitate the cell uptake of nanoparticles. Therefore, TMZ-FaPEC@siRNA of N/P 10 was selected for cell and animal studies. Under TEM observation, TMZ-FaPEC@siRNA of N/P 10 showed a spherical 
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The TMZ release from TMZ-FaPEC@siRNA of N/P 10 was investigated in vitro at pH 7.4 and 5.0. As shown in Figure 3D , TMZ was slowly released during a prolonged period. It is noteworthy that the TMZ release from TMZFaPEC@siRNA was slower than that from TMZ-FaPEC. Likely, the compact interlayer structure formed by PEI complexation with siRNA may hinder the drug diffusion out of micelle. Moreover, the TMZ release was obviously accelerated at pH 5.0 for both the siRNA-complexed and siRNAfree micelles, as compared with the release at pH 7.4. One possible reason is that PEI turned more positively charged at pH 5.0, which may generate inter/intrachain repulsions to loosen the interlayer structure for easier TMZ diffusion.
study on intracellular distribution
FR-mediated cell uptake of the micelle was investigated. To track the endocytosis of drug and siRNA, Coumarin 6 emitting green fluorescence and SCR-Cy3 (Cy3-labeled SCR) emitting red fluorescence were loaded into the micelle, and rat C6 cells as a typical glioma cell line were used for the study. 23 The FR-enriched C6 cells incubated with Coumarin 6-FaPEC@SCR-Cy3 were observed with laser confocal microscopy and quantitative analysis was carried out with flow cytometry. As shown in Figure 4A , cells incubated with Coumarin 6-FaPEC@SCR-Cy3 for 2 h showed much stronger SCR-Cy3 (red) and Coumarin 6 (green) fluorescence than cells incubated with the nontargeting Coumarin 6-PEC@ SCR-Cy3. Consistently, the quantitative flow cytometry analysis revealed that both the Cy3-positive and Coumarin 6-positive populations increased significantly when the cells were incubated with Coumarin 6-FaPEC@SCR-Cy3 rather than Coumarin 6-PEC@SCR-Cy3 ( Figure 4B ). Moreover, although the fluorescence intensities of Coumarin 6 and SCR-Cy3 were different, distributions of Coumarin 6 fluorescence and SCR-Cy3 fluorescence were nearly identical, that is, mostly around the nuclei and within the cytoplasm. Orange stains in the merged image were generated as a result of red and green fluorescence overlapping ( Figure 4A ). In the presence of 1 mg/L folate, the cell uptake level of Coumarin 6-FaPEC@SCR-Cy3 was obviously decreased according to laser confocal microscopic analysis. Quantitatively, the ratio of Cy3-positive and Coumarin 6-positive cells was almost decreased to the same level as that in cells treated with Coumarin 6-PEC@SCR-Cy3, according to flow cytometric analysis. These results strongly suggested that FR mediated 
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In vitro anticancer activity of TMZ-FaPec@sirNa
The cytotoxicities of FaPEC and PEC carrying SCR were measured by CCK8 assay. As shown in Figure 5A , C6 cells incubated with FaPEC@SCR and PEC@SCR displayed viabilities above 90% even at a high polymer concentration of 100 μg/mL, indicating low cytotoxicity of carrier, which was important for in vivo application. For cells incubated with TMZ-loaded micelles, a negative correlation was observed between the cell viability and TMZ concentration. Moreover, TMZ-FaPEC@siRNA showed obviously higher cytotoxicity than both TMZ-FaPEC and TMZ-PEC ( Figure 5B ). For example, at the TMZ concentration of 120 μg, cells treated with TMZ-FaPEC@siRNA showed 49.09% viability, whereas cells treated with other micelles exhibited .60% viability.
Flow cytometry was conducted to quantitatively evaluate cell apoptosis after treatment with nanocomplexes. As shown in Figure 6 , the control cells without treatment showed an extremely low apoptosis rate of 2.8%. In contrast, TMZFaPEC@siRNA treatment induced the highest cell apoptosis rate around 66% among all treatment groups. The TMZPEC@siRNA, TMZ-FaPEC@SCR, FaPEC@siRNA, and free TMZ treatments only resulted in cell apoptosis rates of 51.2%, 44.9%, 34.3%, and 15.8%, respectively. These results further demonstrated that the anticancer effect in vitro was elevated by combination therapy because the codelivered TMZ and BCL-2 siRNA jointly induced cancer cell apoptosis.
In vitro gene silencing effect
An upregulated expression of BCL-2 was discovered in glioma, which may account for the enhanced proliferation and suppressed apoptosis of glioma cells. 24 Thus, BCL-2 gene silencing in C6 cells was attempted through RNA interference. The expression levels of proapoptotic Bax gene in the Figure 7C and D. These results clearly showed that BCL-2 siRNA and TMZ codelivered by the folate-modified micelle acted together on C6 cells to induce apoptosis by silencing BCL-2 and meanwhile upregulating the expression of Bax.
Therapeutic effect in vivo
In vivo experiments were carried out to evaluate the therapeutic effect of FaPEC carrying both TMZ and BCL-2 siRNA. During the experimental process, the rats in the control group drastically lost weight, with their hair appearing 
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Temozolomide for glioma treatment TMZ-FaPEC@siRNA were 188.87±18.49, 210.72±11.22, and 82.25±11.28 mm 3 , respectively ( Figure 8B ). According to these results, although the siRNA or TMZ alone treatment mediated by the folate-targeted nanocarrier was able to inhibit glioma growth to some extent, the combinative therapy was apparently much more effective. In addition, the rats receiving TMZ-PEC@siRNA showed a tumor volume of 139.04±20.60 mm 3 , indicating a much lower therapeutic effect of the nontargeted combinative therapy than the folate-targeted one. These results demonstrated that the combinative therapy of siRNA and TMZ would be beneficial in the treatment of glioma and the therapeutic effect could be further improved with the folate-targeted codelivery nanocarrier.
As shown in Figure 8C , the survival rates of rats varied with therapeutic regimen. The control group exhibited the lowest survival rate, with no rats surviving after 28 days. In contrast, the highest survival rate appeared in the group treated with TMZ-FaPEC@siRNA, and the other three treatments also exhibited conspicuous therapeutic effects. No animal receiving FaPEC@siRNA or TMZ-FaPEC@SCR survived longer than 35 days and all animals receiving TMZPEC@siRNA died within 39 days. Excitingly, the survival rate of rats receiving TMZ-FaPEC@siRNA group was still as high as 50% at day 39.
H&E stain visualized the histologic changes of the glioma (Figure 9 ). The sections from the control group showed obvious hypercellularity hemorrhage foci as well as polymorphic 
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Temozolomide for glioma treatment nuclei. In contrast, tumor cell necrosis was found to be the most remarkable in the group receiving TMZ-FaPEC@ siRNA, revealing the optimized therapeutic effect achieved by the combinative therapy through folate-targeted codelivery. Finally, immunohistochemical staining was carried out to evaluate the effects of different treatments on the expressions of BCL-2 and Bax proteins in tumor tissues. As can be seen in Figure 9 , BCL-2 or Bax protein was stained brown while the blue stains indicated cell nuclei. In comparison with the control group, after the rats were treated with TMZ-FaPEC@ SCR and FaPEC@siRNA, the expression of BCL-2 was downregulated, whereas the expression of Bax was upregulated. Moreover, both the lowest level of BCL-2 protein and the highest level of Bax protein were observed in the group receiving TMZ-FaPEC@siRNA, which suggested that C6 cells turned highly apoptotic upon the combinative therapy of TMZ and siRNA codelivered by Fa-PEC. This notion was verified by directly measuring cell apoptosis using TUNEL assay ( Figure 9 ). Compared with BCL-2 siRNA or TMZ treatment alone, the combinative therapy exhibited a higher potency to induce the apoptosis of glioma cells, based on which an improved therapeutic outcome was obtained by folate-targeted codelivery of siRNA and TMZ.
Discussion
TMZ is known as the first-line drug in glioma chemotherapy, which induces cancer cell apoptosis by intercalating into DNA and then inhibiting macromolecular biosynthesis. 25 The efficacy of TMZ-based single-drug therapy is limited because of drug resistance. 10, 26 RNAi using single-or doublestranded RNA has found great application potentials in the treatments of various diseases because of its sequence specificity and enhanced safety as it only interferes with the posttranscriptional process. 27, 28 The combination of TMZ chemotherapy and gene therapy is regarded as a promising strategy for glioma treatment. 25 The major challenge is to develop a vector with good biocompatibility and desirable delivery efficiency. 29 Herein, a triblock copolymer FaPEC was used to encapsulate TMZ and siRNA through intermolecular hydrophobic interaction and electrostatic complexation, respectively. Considering the overexpressed FR on C6 cells, FaPEC was modified with folate in order to facilitate the cellular uptake of the codelivery system. The results showed that this dual functional nanoplatform provided remarkable efficacy in codelivering TMZ and siRNA into C6 cells, and meanwhile the carrier itself exhibited low toxicity. A much better delivery efficiency for TMZ and siRNA was achieved by folate-modified nanocomplexes compared with the nontargeting ones, which indicated the folate-guided codelivery event. 19, 22, 30 CCK8 and apoptosis assays showed that the combinative treatment of TMZ and siRNA had a potent effect on cell apoptosis by jointly suppressing the expression of BCL-2 and meanwhile upregulating the expression of Bax, which resulted in the elevated anticancer effect in vitro. As BCL-2 gene is frequently overexpressed in glioma cells, the folate-targeted nanomedicine appeared as a proper candidate to further explore the combined therapeutic effect in vivo. 12, 26 In vivo study showed that codelivery of BCL-2 siRNA and TMZ significantly inhibited the growth of glioma. The survival rate of glioma-bearing rats was much elevated when BCL-2 siRNA and TMZ were jointly administered than used alone, and with folate-targeted strategy, the therapeutic effect would be further enhanced. Immunohistochemical assay clearly showed that BCL-2 siRNA and TMZ codelivered by the folate-targeted micelle acted together to induce C6 cell apoptosis, which could account for the achieved significant tumor inhibition and survival benefit.
We chose direct injection rather than systemic delivery for better delivery efficiency. Due to the existence of BBB, systemic delivery as a means to deliver the folate-targeted nanocarriers to brain tissue was extremely difficult although FR is a suitable glioma target in vivo. 31 However, the unfavorable effect of BBB on delivery may be bypassed through direct local injection. Moreover, nanomedicine applied through intracranial injection may have good chance to be sequestrated inside brain because of the effects of both folatetargeting and BBB-blocked washout. 32 Therefore, the therapeutic effect would probably be impaired if the direct delivery method is changed to systemic delivery. 33 Nevertheless, a careful selection of targeting molecules with high specificity is worthwhile in further systemic delivery studies.
Conclusion
A polymeric micelle based on the triblock copolymer Fa-PEG-PEI-PCL was prepared, with TMZ encapsulated in the core and BCL-2 siRNA complexed by the cationic layer. Both in vitro and in vivo studies demonstrated remarkably efficient codelivery of the two therapeutic agents into C6 glioma cells. Consequently, antiapoptotic BCL-2 gene was effectively silenced, and meanwhile the proapoptotic Bax gene was effectively activated, which led to the most significant tumor apoptosis. In animal study, after the combinative therapy of TMZ and BCL-2 siRNA mediated by folate-targeted nanocarrier, the tumor growth was obviously 
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